I'm in at $11 for 900 shares and $13 for another 500 shares. Looks like it got squeezed a little by shorts, but the future looks bright for this gem. With the FDA and EUA both agreeing to expedited application and processing, and a Phase III trial that ended early because of its overwhelming success, I don't see how this beauty doesn't see $40 in the next 30 days.
The Phase III was going so well that the FDA actually stated “It wouldn't be ethical to continue to give half the trial patients placebos!”, and they asked VERU to prepare for high demand VERU quickly.
Leave a Reply